A phase I evaluation of concomitant rifabutin and didanosine in symptomatic HIV-infected patients

A phase I evaluation of concomitant rifabutin and didanosine in symptomatic HIV-infected patients

It has been suggested that didanosine may undergo hepatic metabolism. Fifteen HIV-infected patients whose conditions were stabilized on twice-daily doses of ddI participated in a Phase I, open-label, pharmacokinetic and safety drug interaction study between rifabutin and ddI.

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of acquired immune deficiency syndromes (1999) 1995-07, Vol.9 (3), p.274
Hauptverfasser: Sahai, Jan, Narang, Prem K, Hawley-Foss, Nanci, Li, Ronald C
Format: Artikel
Sprache:eng
Schlagworte:
HIV
Human immunodeficiency virus
Medical research
Metabolism
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:It has been suggested that didanosine may undergo hepatic metabolism. Fifteen HIV-infected patients whose conditions were stabilized on twice-daily doses of ddI participated in a Phase I, open-label, pharmacokinetic and safety drug interaction study between rifabutin and ddI.
ISSN:1525-4135
1944-7884